1958 related articles for article (PubMed ID: 30600478)
21. [Current therapy of hepatocellular carcinoma with special consideration of new and multimodal treatment concepts].
Göbel T; Blondin D; Kolligs F; Bölke E; Erhardt A
Dtsch Med Wochenschr; 2013 Jul; 138(27):1425-30. PubMed ID: 23801265
[TBL] [Abstract][Full Text] [Related]
22. [Diagnosis and multimodal therapy for hepatocellular carcinoma].
Kolligs FT; Hoffmann RT; op den Winkel M; Bruns CJ; Herrmann K; Jakobs TF; Lamerz R; Trumm C; Zech CJ; Wilkowski R; Graeb C
Z Gastroenterol; 2010 Feb; 48(2):274-88. PubMed ID: 20119895
[TBL] [Abstract][Full Text] [Related]
23. [The treatment of hepatocellular carcinoma: an update].
Vero V; Racco S; Biolato M; Pompili M; Gasbarrini G; Miele L; Grieco A
Minerva Med; 2009 Jun; 100(3):173-93. PubMed ID: 19571783
[TBL] [Abstract][Full Text] [Related]
24. Update on Locoregional Therapies for Liver Cancer: Radiation Segmentectomy.
Dadrass F; Sher A; Kim E
Curr Oncol; 2023 Nov; 30(12):10075-10084. PubMed ID: 38132366
[TBL] [Abstract][Full Text] [Related]
25. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy.
Galle PR; Tovoli F; Foerster F; Wörns MA; Cucchetti A; Bolondi L
J Hepatol; 2017 Jul; 67(1):173-183. PubMed ID: 28323121
[TBL] [Abstract][Full Text] [Related]
26. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
[TBL] [Abstract][Full Text] [Related]
27. Treatment of hepatocellular carcinoma: beyond international guidelines.
Colombo M; Sangiovanni A
Liver Int; 2015 Jan; 35 Suppl 1():129-38. PubMed ID: 25529098
[TBL] [Abstract][Full Text] [Related]
28. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
Kim DY; Han KH
Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
[TBL] [Abstract][Full Text] [Related]
29. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation.
Takeda A; Sanuki N; Tsurugai Y; Iwabuchi S; Matsunaga K; Ebinuma H; Imajo K; Aoki Y; Saito H; Kunieda E
Cancer; 2016 Jul; 122(13):2041-9. PubMed ID: 27062278
[TBL] [Abstract][Full Text] [Related]
30. Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.
Gish RG; Finn RS; Marrero JA
Clin Adv Hematol Oncol; 2013 Apr; 11 Suppl 5():1-22; quiz 2 p following p22. PubMed ID: 23881427
[TBL] [Abstract][Full Text] [Related]
31. Treatment options for hepatocellular carcinoma.
Sandhu DS; Tharayil VS; Lai JP; Roberts LR
Expert Rev Gastroenterol Hepatol; 2008 Feb; 2(1):81-92. PubMed ID: 19072372
[TBL] [Abstract][Full Text] [Related]
32. Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment.
Yegin EG; Oymaci E; Karatay E; Coker A
Hepatobiliary Pancreat Dis Int; 2016 Jun; 15(3):234-56. PubMed ID: 27298100
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in the treatment of hepatocellular carcinoma.
Padhya KT; Marrero JA; Singal AG
Curr Opin Gastroenterol; 2013 May; 29(3):285-92. PubMed ID: 23507917
[TBL] [Abstract][Full Text] [Related]
34. Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era.
Waziry R; Gomaa A; Waked I; Dore GJ
Arab J Gastroenterol; 2018 Mar; 19(1):26-32. PubMed ID: 29506913
[TBL] [Abstract][Full Text] [Related]
35. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.
Llovet JM; De Baere T; Kulik L; Haber PK; Greten TF; Meyer T; Lencioni R
Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):293-313. PubMed ID: 33510460
[TBL] [Abstract][Full Text] [Related]
36. Management strategies for hepatocellular carcinoma: old certainties and new realities.
Mazzoccoli G; Tarquini R; Valoriani A; Oben J; Vinciguerra M; Marra F
Clin Exp Med; 2016 Aug; 16(3):243-56. PubMed ID: 26077653
[TBL] [Abstract][Full Text] [Related]
37. From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world.
Dimitroulis D; Damaskos C; Valsami S; Davakis S; Garmpis N; Spartalis E; Athanasiou A; Moris D; Sakellariou S; Kykalos S; Tsourouflis G; Garmpi A; Delladetsima I; Kontzoglou K; Kouraklis G
World J Gastroenterol; 2017 Aug; 23(29):5282-5294. PubMed ID: 28839428
[TBL] [Abstract][Full Text] [Related]
38. Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective.
Colombo M; Raoul JL; Lencioni R; Galle PR; Zucman-Rossi J; Bañares R; Seehofer D; Neuhaus P; Johnson P
Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):639-51. PubMed ID: 23628963
[TBL] [Abstract][Full Text] [Related]
39. Hepatocellular carcinoma review: current treatment, and evidence-based medicine.
Raza A; Sood GK
World J Gastroenterol; 2014 Apr; 20(15):4115-27. PubMed ID: 24764650
[TBL] [Abstract][Full Text] [Related]
40. Hepatocellular carcinoma: Present and future.
Armengol C; Sarrias MR; Sala M
Med Clin (Barc); 2018 May; 150(10):390-397. PubMed ID: 29096967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
